These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 21989445

  • 21. Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer.
    Leissner P, Verjat T, Bachelot T, Paye M, Krause A, Puisieux A, Mougin B.
    BMC Cancer; 2006 Aug 31; 6():216. PubMed ID: 16945123
    [Abstract] [Full Text] [Related]

  • 22. Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.
    Fuessel S, Erdmann K, Taubert H, Lohse-Fischer A, Zastrow S, Meinhardt M, Bluemke K, Hofbauer L, Fornara P, Wullich B, Baretton G, Magdolen V, Wirth MP, Kotzsch M.
    BMC Cancer; 2014 Dec 18; 14():974. PubMed ID: 25519168
    [Abstract] [Full Text] [Related]

  • 23. Prognostic value of intercellular adhesion molecule (ICAM)-1 expression in breast cancer.
    Schröder C, Witzel I, Müller V, Krenkel S, Wirtz RM, Jänicke F, Schumacher U, Milde-Langosch K.
    J Cancer Res Clin Oncol; 2011 Aug 18; 137(8):1193-201. PubMed ID: 21590495
    [Abstract] [Full Text] [Related]

  • 24. Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer.
    Schmitt M, Thomssen C, Ulm K, Seiderer A, Harbeck N, Höfler H, Jänicke F, Graeff H.
    Br J Cancer; 1997 Aug 18; 76(3):306-11. PubMed ID: 9252196
    [Abstract] [Full Text] [Related]

  • 25. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
    Konecny G, Untch M, Arboleda J, Wilson C, Kahlert S, Boettcher B, Felber M, Beryt M, Lude S, Hepp H, Slamon D, Pegram M.
    Clin Cancer Res; 2001 Aug 18; 7(8):2448-57. PubMed ID: 11489825
    [Abstract] [Full Text] [Related]

  • 26. Limited prognostic value of c-erbB-2 compared to uPA and PAI-1 in primary breast carcinoma.
    Bouchet C, Ferrero-Poüs M, Hacène K, Becette V, Spyratos F.
    Int J Biol Markers; 2003 Aug 18; 18(3):207-17. PubMed ID: 14535592
    [Abstract] [Full Text] [Related]

  • 27. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
    Grøndahl-Hansen J, Christensen IJ, Briand P, Pappot H, Mouridsen HT, Blichert-Toft M, Danø K, Brünner N.
    Clin Cancer Res; 1997 Feb 18; 3(2):233-9. PubMed ID: 9815678
    [Abstract] [Full Text] [Related]

  • 28. Urokinase plasminogen activator and its inhibitor type-1 as prognostic factors in differentiated thyroid carcinoma patients.
    Horvatic Herceg G, Herceg D, Kralik M, Kulic A, Bence-Zigman Z, Tomic-Brzac H, Bracic I, Kusacic-Kuna S, Prgomet D.
    Otolaryngol Head Neck Surg; 2013 Oct 18; 149(4):533-40. PubMed ID: 23835563
    [Abstract] [Full Text] [Related]

  • 29. [Prognostic value of urokinase-type plasminogen activator and 2 inhibitors PAI-1 and PAI-2 in breast cancer].
    Bouchet C, Spyratos F, Martin PM, Hacène K, Gentile A, Oglobine J.
    Bull Cancer; 1994 Sep 18; 81(9):770-9. PubMed ID: 7703566
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Clinical significance of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) for metastatic sentinel lymph node involvement in breast cancer.
    Harms W, Malter W, Krämer S, Drebber U, Drzezga A, Schmidt M.
    Anticancer Res; 2014 Aug 18; 34(8):4457-62. PubMed ID: 25075085
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Association of uPA, PAT-1, and uPAR in nipple aspirate fluid (NAF) with breast cancer.
    Qin W, Zhu W, Wagner-Mann C, Folk W, Sauter ER.
    Cancer J; 2003 Aug 18; 9(4):293-301. PubMed ID: 12967140
    [Abstract] [Full Text] [Related]

  • 34. Markers of progression and invasion in short term follow up of untreated breast cancer patients.
    Rabi ZA, Todorović-Raković N, Vujasinović T, Milovanović J, Nikolić-Vukosavljević D.
    Cancer Biomark; 2015 Aug 18; 15(6):745-54. PubMed ID: 26406416
    [Abstract] [Full Text] [Related]

  • 35. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer.
    Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H, Graeff H.
    Breast Cancer Res Treat; 1993 Aug 18; 24(3):195-208. PubMed ID: 8435475
    [Abstract] [Full Text] [Related]

  • 36. Prognostic and predictive value of the urokinase-type plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in operable breast cancer.
    Cufer T, Borstnar S, Vrhovec I.
    Int J Biol Markers; 2003 Aug 18; 18(2):106-15. PubMed ID: 12841679
    [Abstract] [Full Text] [Related]

  • 37. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
    Kim SJ, Shiba E, Kobayashi T, Yayoi E, Furukawa J, Takatsuka Y, Shin E, Koyama H, Inaji H, Takai S.
    Clin Cancer Res; 1998 Jan 18; 4(1):177-82. PubMed ID: 9516968
    [Abstract] [Full Text] [Related]

  • 38. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
    Hildenbrand R, Schaaf A, Dorn-Beineke A, Allgayer H, Sütterlin M, Marx A, Stroebel P.
    Histol Histopathol; 2009 Jul 18; 24(7):869-77. PubMed ID: 19475533
    [Abstract] [Full Text] [Related]

  • 39. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
    Hundsdorfer B, Zeilhofer HF, Bock KP, Dettmar P, Schmitt M, Kolk A, Pautke C, Horch HH.
    J Craniomaxillofac Surg; 2005 Jun 18; 33(3):191-6. PubMed ID: 15878520
    [Abstract] [Full Text] [Related]

  • 40. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
    Costantini V, Sidoni A, Deveglia R, Cazzato OA, Bellezza G, Ferri I, Bucciarelli E, Nenci GG.
    Cancer; 1996 Mar 15; 77(6):1079-88. PubMed ID: 8635127
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.